FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981294404> ?p ?o ?g. }

• W2981294404 endingPage "2601" @default.
• W2981294404 startingPage "2601" @default.
• W2981294404 abstract "Abstract Leukemia cells survive and proliferate under conditions of metabolic stress by acquiring mutations that increase energy metabolism. Here, we aimed to identify a specific metabolic inhibitor and examine transcription factor-enhanced changes in energy metabolism by refractory leukemia cells. Overexpression of Ecotropic Virus Integration site 1 protein homolog (EVI1) in adults and children with mixed lineage leukemia-rearrangement acute myeloid leukemia (MLL-r AML) has a very poor prognosis. We focused on metabolic reprograming of MLL leukemia cells expressing EVI1, since the metabolic relationship between MLL and EVI1 is unclear. We used an extracellular flux analyze to examine metabolic changes during leukemia development in a mouse model of MLL-r AML expressing high levels of EVI1 (EVI1+). To examine whether EVI1 regulates energy metabolism in MLL-rearranged leukemia cells, we used transgenic mice expressing EVI1 (TG) in LSK and GMP cells model in which AML is driven by the MLL-AF9 oncogene. We measured oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) using a flux analyzer. TG MLL-AF9 mice showed a significantly higher basal and capacity of OCR than WT MLL-AF9 mice ex vivo. EVI1+ cells showed accelerated oxidative phosphorylation (OXPHOS) prior to activation of glycolysis, and higher dependency on glutamine as an energy source. To identify the metabolic pathways regulated by EVI1, we performed capillary electrophoresis time-of-fight mass spectrometry-based metabolome profiling of WT and TG MLL-AF9 leukemia cells. We found significant differences between the cells in terms of the amounts of metabolites derived from the glycolytic and TCA cycles. Fructose 1,6-bisphosphate and lactate were up-regulated in TG MLL-AF9 cells, implying activation of glycolysis. Moreover, the amounts of fumarate and malate (metabolites of the TCA cycle) were significantly higher in TG MLL-AF9 cells. EVI1 played a role in glycolysis as well as driving expression of genes engaged in the tricarboxylic acid cycle. Next, we tested whether pharmacological inhibition of glycolysis and glutaminolysis suppresses MLL-AF9. L-asparaginase (ASP) [which catalyzes hydrolysis of asparagine (Asn) and glutamine (Gln) to asparatic acid or glutamic acid, respectively] markedly suppressed proliferation of TG MLL-AF9 cells, EVI1highAML cell lines. To examine the therapeutic potential of ASP in vivo, we treated secondary recipients of TG MLL-AF9 AML cells with ASP or control (vehicle), beginning 5 days post-transplantation. Mice then received intraperitoneal injections (five times per week) of distilled water or ASP (1000 U/kg). ASP led to a significant reduction in the number of GFP+ AML cells in the peripheral blood and increased the survival of recipient mice. Next, we examined an AML xenograft model. Two groups of NOG mice were injected subcutaneously with UCSD/AML1 cells and then treated with ASP or control. ASP -treated mice showed a significant reduction in the growth of AML tumors. Overall, these findings indicate that ASP -mediated inhibition of OXPHOS is a potential treatment for AML. We clarified that increased glutamine dependency by MLL-r AML cells showing high EVI1 expression makes them sensitive to ASP. We found that the energy advantage of AML cells is acquired via transcription factor-mediated activation of mitochondrial metabolism, leading to a poor prognosis. Furthermore, we show that new therapeutic options can be identified by examining the energy-based metabolic characteristics of leukemia cells. Disclosures No relevant conflicts of interest to declare." @default.
• W2981294404 created "2019-10-25" @default.
• W2981294404 creator A5006196521 @default.
• W2981294404 creator A5023389902 @default.
• W2981294404 creator A5033914337 @default.
• W2981294404 creator A5034999696 @default.
• W2981294404 creator A5038138665 @default.
• W2981294404 creator A5053911733 @default.
• W2981294404 creator A5082253523 @default.
• W2981294404 creator A5090382710 @default.
• W2981294404 date "2018-11-29" @default.
• W2981294404 modified "2023-09-30" @default.
• W2981294404 title "EVI1 in Acute Myeloid Leukemia Triggers Metabolic Reprograming Associated with Leukemogenesis and Increases Sensitivity to L-Aspalaginase" @default.
• W2981294404 doi "https://doi.org/10.1182/blood-2018-99-111581" @default.
• W2981294404 hasPublicationYear "2018" @default.
• W2981294404 type Work @default.
• W2981294404 sameAs 2981294404 @default.
• W2981294404 citedByCount "0" @default.
• W2981294404 crossrefType "journal-article" @default.
• W2981294404 hasAuthorship W2981294404A5006196521 @default.
• W2981294404 hasAuthorship W2981294404A5023389902 @default.
• W2981294404 hasAuthorship W2981294404A5033914337 @default.
• W2981294404 hasAuthorship W2981294404A5034999696 @default.
• W2981294404 hasAuthorship W2981294404A5038138665 @default.
• W2981294404 hasAuthorship W2981294404A5053911733 @default.
• W2981294404 hasAuthorship W2981294404A5082253523 @default.
• W2981294404 hasAuthorship W2981294404A5090382710 @default.
• W2981294404 hasBestOaLocation W29812944041 @default.
• W2981294404 hasConcept C135870905 @default.
• W2981294404 hasConcept C20251656 @default.
• W2981294404 hasConcept C203014093 @default.
• W2981294404 hasConcept C2777477808 @default.
• W2981294404 hasConcept C2778461978 @default.
• W2981294404 hasConcept C2778729363 @default.
• W2981294404 hasConcept C2779282312 @default.
• W2981294404 hasConcept C502942594 @default.
• W2981294404 hasConcept C55493867 @default.
• W2981294404 hasConcept C62231903 @default.
• W2981294404 hasConcept C86803240 @default.
• W2981294404 hasConceptScore W2981294404C135870905 @default.
• W2981294404 hasConceptScore W2981294404C20251656 @default.
• W2981294404 hasConceptScore W2981294404C203014093 @default.
• W2981294404 hasConceptScore W2981294404C2777477808 @default.
• W2981294404 hasConceptScore W2981294404C2778461978 @default.
• W2981294404 hasConceptScore W2981294404C2778729363 @default.
• W2981294404 hasConceptScore W2981294404C2779282312 @default.
• W2981294404 hasConceptScore W2981294404C502942594 @default.
• W2981294404 hasConceptScore W2981294404C55493867 @default.
• W2981294404 hasConceptScore W2981294404C62231903 @default.
• W2981294404 hasConceptScore W2981294404C86803240 @default.
• W2981294404 hasIssue "Supplement 1" @default.
• W2981294404 hasLocation W29812944041 @default.
• W2981294404 hasOpenAccess W2981294404 @default.
• W2981294404 hasPrimaryLocation W29812944041 @default.
• W2981294404 hasRelatedWork W1516501920 @default.
• W2981294404 hasRelatedWork W1974032072 @default.
• W2981294404 hasRelatedWork W2012639655 @default.
• W2981294404 hasRelatedWork W2095662532 @default.
• W2981294404 hasRelatedWork W2323897006 @default.
• W2981294404 hasRelatedWork W2520871879 @default.
• W2981294404 hasRelatedWork W2791968852 @default.
• W2981294404 hasRelatedWork W2990397977 @default.
• W2981294404 hasRelatedWork W3096003772 @default.
• W2981294404 hasRelatedWork W3207807551 @default.
• W2981294404 hasVolume "132" @default.
• W2981294404 isParatext "false" @default.
• W2981294404 isRetracted "false" @default.
• W2981294404 magId "2981294404" @default.
• W2981294404 workType "article" @default.